Somatic mutations in human cancer: applications in molecular epidemiology.
暂无分享,去创建一个
[1] H. Whittle,et al. Ser‐249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa , 2004, International journal of cancer.
[2] T. Kunkel. DNA Replication Fidelity* , 2004, Journal of Biological Chemistry.
[3] D. Choubey,et al. Resistance to UV‐induced apoptosis in human keratinocytes during accelerated senescence is associated with functional inactivation of p53 , 2004, Journal of cellular physiology.
[4] U. Moll,et al. The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.
[5] Jürgen Geisler,et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] P. Hanawalt,et al. Functional characterization of global genomic DNA repair and its implications for cancer. , 2003, Mutation research.
[7] L. Donehower,et al. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis , 2003, Oncogene.
[8] Paul T Strickland,et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. , 2003, Carcinogenesis.
[9] P. Hainaut,et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. , 2003, The Journal of thoracic and cardiovascular surgery.
[10] B. Gusterson,et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.
[11] Ding-Shinn Chen,et al. Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.
[12] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[13] J. Essigmann,et al. The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[14] P. Hainaut,et al. Genotoxic and non-genotoxic pathways of p53 induction. , 2001, Cancer Letters.
[15] Yaolin Wang,et al. Analyses of p53 Target Genes in the Human Genome by Bioinformatic and Microarray Approaches* 210 , 2001, The Journal of Biological Chemistry.
[16] Jacques Ferlay,et al. Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.
[17] J. Essigmann,et al. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. , 2001, Carcinogenesis.
[18] R. Vossen,et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.
[19] P. Hainaut,et al. New approaches to understanding p53 gene tumor mutation spectra. , 1999, Mutation research.
[20] P. May,et al. Twenty years of p53 research: structural and functional aspects of the p53 protein , 1999, Oncogene.
[21] D. Bell,et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. , 1999, Cancer research.
[22] G. Capellá,et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Harris,et al. Hepatitis B virus X protein inhibits nucleotide excision repair , 1999, International journal of cancer.
[24] A. Riggs,et al. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts , 1998, Oncogene.
[25] C. Potten,et al. Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and cell cycle arrest. , 1998, The American journal of pathology.
[26] L. Bracco,et al. The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.
[27] A. Børresen-Dale,et al. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. , 1998, British Journal of Cancer.
[28] K. McLure,et al. How p53 binds DNA as a tetramer , 1998, The EMBO journal.
[29] L. Mullenders,et al. Transcription coupled repair and its impact on mutagenesis. , 1998, Mutation research.
[30] K. Kinzler,et al. The Genetic Basis of Human Cancer , 1997 .
[31] Chien-Jen Chen,et al. Epidemiological characteristics and risk factors of hepatocellular carcinoma , 1997, Journal of gastroenterology and hepatology.
[32] C. Harris,et al. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. , 1997, Carcinogenesis.
[33] G. Wahl,et al. p53 Mediates Permanent Arrest over Multiple Cell Cycles in Response to γ-Irradiation , 1997 .
[34] R. Birgander,et al. Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.
[35] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[36] J. Essigmann,et al. The relationship between the chemical structures and mutagenic specificities of the DNA lesions formed by chemical and physical mutagens. , 1993, Toxicology letters.
[37] B. Henderson,et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma , 1992, The Lancet.
[38] A. Puisieux,et al. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. , 1991, Cancer research.
[39] P Mandel,et al. Les acides nucleiques du plasma sanguin chez l' homme , 1948 .
[40] H. Mulcahy,et al. Detection of Circulating Tumour DNA in the Blood (Plasma/Serum) of Cancer Patients , 2004, Cancer and Metastasis Reviews.
[41] M. Kastan,et al. ATM--a key determinant of multiple cellular responses to irradiation. , 2001, Acta oncologica.
[42] M. Hollstein,et al. p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.
[43] P. Hainaut,et al. Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[44] A. Børresen-Dale,et al. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] P. Hainaut,et al. The use of biomarkers to study pathogenesis and mechanisms of cancer: oesophagus and skin cancer as models. , 1997, IARC scientific publications.
[46] Stylianos E. Antonarakis,et al. The nature and mechanisms of human gene mutation , 1995 .
[47] M. Stroun,et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. , 1989, Oncology.